关于慢性乙型肝炎LLV患者的相关临床研究
Clinical Research on LLV Patients with Chronic Hepatitis B
摘要: 2016年世界卫生组织提出2030年消除病毒性肝炎作为重大公共卫生危害的目标，并提出死亡率下降65%的明确目标。然而，经NAs类药物长期治疗后仍出现LLV的情况，并严重影响其预后如：促进肝纤维化进展、加重肝硬化和肝癌的发生。本文总结LLV的定义及发生率，发生概况及选择，对LLV的存在对CHB患者的影响进行综述，以供临床医师参考。
Abstract: In 2016, the World Health Organization set a target of eliminating hepatitis as a major public health hazard by 2030, with a clear goal of reducing mortality by 65 percent. However, LLV still occurs af-ter long-term treatment with NAS drugs, which can seriously affect the prognosis of patients, such as promoting the progression of liver fibrosis, aggravating the occurrence of liver cirrhosis and liver cancer. This article summarized the definition and incidence of LLV, the general situation of occur-rence and selection, and the influence of the existence of LLV on CHB patients, so as to provide ref-erence for clinicians.
文章引用：杨琳, 路少非, 高晓红. 关于慢性乙型肝炎LLV患者的相关临床研究[J]. 临床医学进展, 2023, 13(8): 13038-13044. https://doi.org/10.12677/ACM.2023.1381826

参考文献

[1] 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274.
[2] European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398.
[3] Kim, J.H., Sinn, D.H., Kang, W., et al. (2017) Low-Level Viremia and the Increased Risk of Hepatocellular Carcinoma in Patients Re-ceiving Entecavir Treatment. Hepatology, 66, 335-343. [Google Scholar] [CrossRef] [PubMed]
[4] 尤红, 王福生, 李太生, 孙亚朦, 徐小元, 贾继东, 南月敏, 王贵强, 侯金林, 魏来, 段钟平, 庄辉. 慢性乙型肝炎防治指南(2022年版) [J]. 传染病信息, 2023, 36(1): 1-17.
[5] Xing, M., Sen, L., Jane, D. and Andrew, G.I. (2020) Chronic Hepatitis B Management in Clinical Practice in Fuzhou Province, China: Retrospective Cross-Sectional Analysis of Electronic Medical Record Data. Hepatology International, 14, 1-470. [Google Scholar] [CrossRef] [PubMed]
[6] 王健, 吴东洋, 郑建兴, 张金凤, 王利民. 恩替卡韦治疗HBeAg阳性慢性乙型肝炎抗病 效应评估[J]. 中华医院感染学杂志, 2023, 33(5): 652-656.
[7] Haché, C. and Villeneuve, J.P. (2006) Lamivudine Treatment in Patients with Chronic Hepatitis B and Cirrhosis. Expert Opinion on Pharmacotherapy, 7, Article ID: 183543. [Google Scholar] [CrossRef] [PubMed]
[8] Manns, M.P., Akarca, U.S., Chang, T.T., et al. (2012) Long-Term Safety and Tolerability of Entecavir in Patients with Chronic Hepatitis B in the Rollover Study ETV-901. Ex-pert Opinion on Drug Safety, 11, 361-368. [Google Scholar] [CrossRef] [PubMed]
[9] Sun, Y., Wu, X., Zhou, J., et al. (2020) Persistent Low-Level of Hepatitis B Virus Promotes Fibrosis Progression during Therapy. Clinical Gastroenterology and Hepatology, 18, 2582-2591. [Google Scholar] [CrossRef] [PubMed]
[10] 陈贺, 傅涓涓, 李丽, 等. 长期恩替卡韦经治慢性乙型肝炎患者低病毒血症的相关影响因素[J]. 临床肝胆病杂志, 2021, 37(3): 556-559.
[11] Agarwal, K., Brunetto, M., Seto, W.K., et al. (2018) 96 Weeks Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Hepatitis B Virus Infection. Journal of Hepatology, 68, 672-681. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, X.Y., Ren, S., Lu, J., et al. (2022) Combination Therapy in HBeAg-Negative Chronic Hepatitis B Patients with Low-Level Viremia to Nucleos (Tide) Analogues [c]. EASL, Ab-stracts (SAT382), London.
[13] 孙亚朦, 贾继东, 尤红. 2022年《扩大慢性乙型肝炎抗病毒治疗的专家意见》解读[J]. 中国临床医生杂志, 2022, 50(10): 1144-1146.
[14] Zhang, S., Zhang, X., Jin, H., Dou, Y., Li, L., Yuan, X., Dong, C., Hou, M., Nan, Y.M. and Shang, J. (2023) Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B. Journal of Clinical and Translational Hepatology, 11, 67-75.
[15] 宣碧碧, 徐永红, 杜忠彩, 刘玉, 杨玉玲, 边城. 慢性乙型肝炎和乙型肝炎肝硬化患者发生低病毒血症的影响因素及其与肝脏炎症、肝纤维化进展的关系[J]. 临床肝胆病杂志, 2022, 38(10): 2252-2259.
[16] Lee, S.B., Jeong, J., Park, J.H., Jung, S.W., Jeong, I.D., Bang, S.J., et al. (2020) Low-Level Viremia and Cirrhotic Complications in Patients with Chronic Hepatitis B According to Adherence to Entecavir. Clinical and Molecular Hepatology, 26, 364-375. [Google Scholar] [CrossRef] [PubMed]
[17] 周洪波, 刘丹阳, 吕丹, 袁立红. 不同核苷酸类药物治疗慢性乙型病毒性肝炎患者的临床效果[J]. 中国药物经济学, 2021, 16(8): 51-54.
[18] Yim, H.J., Kim, I.H., Suh, S.J., Jung, Y.K., Kim, J.H., Seo, Y.S., et al. (2018) Switching to Tenofovir vs Continuing Entecavir for Hepatitis B Virus with Par-tial Virologic Response to Entecavir: A Randomized Controlled Trial. Journal of Viral Hepatitis, 25, 1321-1330. [Google Scholar] [CrossRef] [PubMed]
[19] Papatheodoridis, G.V., Manesis, E.K., Manolakopoulos, S., Elefsiniotis, I.S., Goulis, J., Giannousis, J., et al. (2008) Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen-Negative Chronic Hepatitis B Virus Infection? Hepatology, 48, 1451-1459. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, Q., Peng, H., Liu, X., Wang, H., Du, J., Luo, X., et al. (2021) Chronic Hepatitis B Infection with Low-Level Viremia Correlates with the Progression of the Liver Disease. Journal of Clinical and Translational Hepatology, 9, 850-859. [Google Scholar] [CrossRef] 
[21] 陈词. 罗新华: 慢乙肝合并脂肪肝的抗病毒治疗及预后[J]. 肝博士, 2019(4): 26-27.
[22] Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[23] Machado, M.V., Oliveira, A.G. and Cortez-Pinto, H. (2011) Hepatic Stea-tosis in Hepatitis B Virus Infected Patients: Meta-Analysis of Risk Factors and Comparison with Hepatitis C Infected Pa-tients. Journal of Gastroenterology and Hepatology, 26, 1361-1367. [Google Scholar] [CrossRef] [PubMed]
[24] Hui, R.W.H., Seto, W.K., Cheung, K.S., et al. (2018) In-verse Relationship between Hepatic Steatosis and Hepatitis B Viremia: Results of a Large Case-Control Study. Journal of Viral Hepatitis, 25, 97-104. [Google Scholar] [CrossRef] [PubMed]
[25] Minakari, M., Molaei, M., Shalmani, H.M., et al. (2009) Liver Steatosis in Patients with Chronic Hepatitis B Infection: Host and Viral Risk Factors. European Journal of Gastroenterology & Hepatology, 21, 512-516. [Google Scholar] [CrossRef] 
[26] Mak, L.Y., Hui, R.W., Fung, J., et al. (2020) Diverse Ef-fects of Hepatic Steatosis on Fibrosis Progression and Functional Cure in Virologically Quiescent Chronic Hepatitis B. Journal of Hepatology, 73, 800-806. [Google Scholar] [CrossRef] [PubMed]
[27] Ya, M.S., Xiao, N.W., Jia, L.Z. and Tong, T. (2020) Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression during Therapy. Clinical Gastroenterology and Hepa-tology, 18, 2582-2591.e6. [Google Scholar] [CrossRef] [PubMed]
[28] 叶晓晓, 杨海飞, 张赛君. 不同HBV DNA载量慢性乙型肝炎患儿肝脏病理肝功能及血纤维化指标变化对照研究[J]. 中国妇幼保健, 2021, 36(8): 1790-1792.
[29] Kim, J.H. and Sinn, D.H. (2020) Low-Level Viremia in Patients Undergoing Antiviral Therapy: Does It Indicate Time for a Change? Clinical and Molecular Hepatology, 26, 315-317. [Google Scholar] [CrossRef] [PubMed]
[30] Burns, G.S. and Thompson, A.J. (2014) Viral Hepatitis B: Clinical and Epidemiological Characteristics. Cold Spring Harbor Perspectives in Medicine, 4, a024935. [Google Scholar] [CrossRef] [PubMed]
[31] Yenilmez, E., Çetinkaya, R.A. and Tural, E. (2018) Diagnostic Dilemma for Low Viremia with Significant Fibrosis; Is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage? Balkan Medical Journal, 35, 326-332. [Google Scholar] [CrossRef] [PubMed]

为你推荐